scholarly journals Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials

1995 ◽  
Vol 72 (2) ◽  
pp. 469-475 ◽  
Author(s):  
JF Tierney ◽  
V Mosseri ◽  
LA Stewart ◽  
RL Souhami ◽  
MKB Parmar
Keyword(s):  
Clinical Trials ◽  
Adjuvant Chemotherapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Meta Analysis ◽  
Randomised Clinical Trials

scholarly journals A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma

Cancer ◽  
2008 ◽  
Vol 113 (3) ◽  
pp. 573-581 ◽  
Author(s):  
Nabeel Pervaiz ◽  
Nigel Colterjohn ◽  
Forough Farrokhyar ◽  
Richard Tozer ◽  
Alvaro Figueredo ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled

scholarly journals Adjuvant Chemotherapy Following Complete Resection of Soft Tissue Sarcoma in Adults: A Clinical Practice Guideline

Sarcoma ◽  
2002 ◽  
Vol 6 (1) ◽  
pp. 5-18 ◽  
Author(s):  
Alvaro Figueredo ◽  
Vivien H. C. Bramwell ◽  
Robert Bell ◽  
Aileen M. Davis ◽  
Manya L. Charette ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Practice Guideline ◽  
Randomized Clinical Trials ◽  
Histological Grade ◽  
Meta Analysis ◽  
High Histological Grade ◽  
Meta Analyses

Purpose. To review the literature and make recommendations for the use of anthracycline-based adjuvant chemotherapy in adult patients with soft tissue sarcoma (STS).Patients. The recommendations apply to patients >15 years old with completely resected STS.Methods. A systematic overview of the published literature was combined with a consensus process around the interpretation of the evidence in the context of conventional practice to develop an evidence-based practice guideline.Results. Four meta-analyses and 17 randomized clinical trials comparing anthracycline-based adjuvant chemotherapy versus observation were reviewed. The Sarcoma Meta-Analysis Collaboration (SMAC) was the best analysis because it assessed individual patient data and had the longest follow-up. The results of the SMAC meta-analysis together with data from more recently published randomized trials, as well as our analysis of the toxicity and compliance data, are incorporated in this systematic review.Discussion. It is reasonable to consider anthracycline-based adjuvant chemotherapy in patients who have had removal of a sarcoma with features predicting a high likelihood of relapse (deep location, size >5 cm, high histological grade). Although the benefits of adjuvant chemotherapy are most apparent in patients with extremity sarcomas, patients with high-risk tumours at other sites should also be considered for such therapy.

scholarly journals Comparison of Different Systemic Therapeutic Regimes in Resectable Soft-Tissue Sarcoma—Results of a Network Meta-Analysis

Cancers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 5631
Author(s):  
Jan Haussmann ◽  
Christiane Matuschek ◽  
Edwin Bölke ◽  
Balint Tamaskovics ◽  
Stefanie Corradini ◽  
...  
Keyword(s):  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Literature Search ◽  
Standard Treatment ◽  
Meta Analysis ◽  
Treatment Modalities ◽  
Regional Hyperthermia ◽  
Male Patients

Background: The standard treatment of high-risk soft-tissue sarcoma consists of surgical resection followed by risk-adapted radiation therapy. Further treatment options that may improve local and systemic tumor control, including chemotherapy, are not well established. Due to the heterogeneity of the disease, different systemic approaches as well as their application at different time points have been attempted. Methods: We conducted a systematic literature search for randomized clinical trials in the treatment of localized, resectable high-risk adult soft-tissue sarcoma comparing different treatment modalities according to the PRISMA guidelines. We extracted published hazard ratios and number of events for the endpoints overall and disease-free survival (OS; DFS) as well as local and distant recurrence-free interval (LRFI; DRFI). The different modalities were compared in a network meta-analysis against the defined standard treatment surgery ± radiotherapy using the inverse-variance heterogeneity model. Results: The literature search identified 25 trials including 3453 patients. Five different treatment modalities were compared in the network meta-analysis. The addition of adjuvant chemotherapy significantly improved OS compared to surgery ± radiotherapy alone (HR = 0.86; CI-95%: 0.75–0.97; p = 0.017). Likewise, neoadjuvant chemotherapy combined with regional hyperthermia (naCTx + HTx) also led to superior OS (HR = 0.45; CI-95%: 0.20–1.00; p = 0.049). Both neoadjuvant chemotherapy alone (naCTx) and perioperative chemotherapy (periCTx) did not improve OS (HR = 0.61; CI-95%: 0.29–1.29; p = 0.195 and HR = 0.66; CI-95%: 0.30–1.48; p = 0.317, respectively). Histology-tailored chemotherapy (htCTx) also did not improve survival compared to surgery ± radiotherapy (HR = 1.08; CI-95%: 0.45–2.61; p = 0.868). The network analysis of DFS, LRFI, and DRFI revealed a similar pattern between the different treatment regimens. Adjuvant chemotherapy significantly improved DFS, LRFI, and DRFI compared to surgery ± radiotherapy. In direct comparison, this advantage of adjuvant chemotherapy was restricted to male patients (HR = 0.78; CI-95%: 0.65–0.92; p = 0.004) with no effect for female patients (HR = 1.08; CI-95%: 0.90–1.29; p = 0.410). Conclusions: Standardized chemotherapy in high-risk soft-tissue sarcoma appears to be of added value irrespective of timing. The benefit of adjuvant chemotherapy seems to be restricted to male patients. The addition of regional hyperthermia to neodjuvant chemotherapy achieved the best effect sizes and might warrant further investigation.

Adjuvant chemotherapy in soft tissue sarcoma (STS): A meta-analysis of published data

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 10526-10526 ◽  
Author(s):  
J. M. O’Connor ◽  
M. Chacón ◽  
F. E. Petracci ◽  
R. D. Chacón
Keyword(s):  
Adjuvant Chemotherapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Meta Analysis ◽  
Published Data

scholarly journals Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials

2014 ◽  
Vol 25 (12) ◽  
pp. 2425-2432 ◽  
Author(s):  
A. Le Cesne ◽  
M. Ouali ◽  
M.G. Leahy ◽  
A. Santoro ◽  
H.J. Hoekstra ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Adjuvant Chemotherapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Pooled Analysis ◽  
Phase Iii ◽  
Phase Iii Clinical Trials
Sign in / Sign up

Export Citation Format

Share Document